8-K: Revelation Biosciences Faces Nasdaq Delisting Threat Due to Minimum Bid Price and Equity Deficiencies

Revelation Biosciences has received notification from Nasdaq regarding non-compliance with minimum bid price and stockholders' equity requirements, potentially leading to delisting.

Summary

• Revelation Biosciences received a letter from Nasdaq on October 16, 2024, stating they are not compliant with the minimum bid price requirement of $1.00 per share.
• The company is ineligible for the standard 180-day compliance period due to previous reverse stock splits.
• Separately, Revelation Biosciences was notified on August 14, 2024, that they do not meet the minimum stockholders' equity requirement of $2,500,000.
• The company also does not meet alternative listing standards related to market value or net income.
• The minimum bid price deficiency serves as an additional basis for delisting due to the existing stockholders' equity deficiency.
• Revelation Biosciences believes it met the stockholders' equity requirement as of September 30, 2024, due to financing activities.
• The company intends to appeal the delisting notices and request a hearing.
• The appeal will stay any delisting action pending the hearing outcome.
• There is no guarantee that the company will regain compliance with Nasdaq listing requirements.
• The company's stock and warrants will continue to trade on Nasdaq under the symbols REVB and REVBW, respectively, while the appeal process is underway.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting threat and non-compliance with Nasdaq listing rules. While the company intends to appeal, there is no guarantee of success.

Positives

• The company believes it has met the stockholders' equity requirement as of September 30, 2024.
• The company intends to appeal the delisting notices and request a hearing, which will stay any delisting action.
• The company's stock and warrants will continue to trade on Nasdaq while the appeal process is underway.

Negatives

• The company is not in compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• The company is not eligible for the standard 180-day compliance period due to previous reverse stock splits.
• The company was also notified that they do not meet the minimum stockholders' equity requirement of $2,500,000.
• There is no guarantee that the company will regain compliance with Nasdaq listing requirements.

Risks

• The company faces the risk of being delisted from Nasdaq if it cannot regain compliance with listing requirements.
• The company's stock price could be negatively impacted by the delisting threat.
• There is no guarantee that the company will be successful in its appeal to Nasdaq.
• The company's ability to raise capital may be affected by the delisting threat.

Future Outlook

The company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq, including appealing the delisting notices and requesting a hearing.

Management Comments

• The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq.
• The Company has the right to appeal the Deficiency Letters by requesting a hearing before an independent panel, which it intends to do prior to the deadline for filing such appeal.

Industry Context

This announcement highlights the challenges faced by smaller biotech companies in maintaining listing compliance, particularly in volatile market conditions. Many companies in the sector face similar challenges related to funding and stock performance.

Comparison to Industry Standards

• Many small-cap biotech companies struggle to maintain Nasdaq listing compliance, particularly during periods of market volatility.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have faced similar delisting threats due to low stock prices, highlighting the common challenges in the sector.
• The minimum bid price requirement is a standard listing rule, and failure to meet it is a common reason for delisting notices.
• The stockholders' equity requirement is also a standard listing rule, and companies with limited revenue or ongoing losses often struggle to maintain compliance.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• Employees may be concerned about the company's future prospects.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will request a hearing before an independent panel to appeal the delisting notices.
• The company will work to regain compliance with Nasdaq listing requirements.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, stockholders' equity, compliance, reverse stock split, appeal, REVB, REVBW